Trial Profile

A Phase 1/2, Open-label, Multi-center Study to Evaluate theSafety and Efficacy of Selinexor Combined With Chemotherapy orTislelizumab in Relapsed or Refractory Mature T and NK Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary) ; Tislelizumab (Primary) ; Carboplatin; Etoposide; Gemcitabine; Ifosfamide; Mesna; Oxaliplatin
Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Peripheral T-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms TOUCH
Sponsors Antengene Corporation

Most Recent Events

06 Jun 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
06 Jun 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
09 Dec 2024 According to an Antengene Corporation media release, data from this study were presented at the 2024 American Society of Hematology Annual Meeting (ASH 2024).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com